A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
A phase 1/2 trial of Radiopharmaceuticals in prostate cancer, run by C Ray Therapeutics, now recruiting.
Overview
A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC is a phase 1/2 interventional study registered as NCT07567521 by C Ray Therapeutics, with 90 participants planned, started 2026-05-22 and due to reach its primary completion in 2027-12-30. Interventions recorded: Radiopharmaceuticals.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, PSMA, Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares Metastatic castration-resistant prostate cancer, PSMA, Prostate cancer and the tag pipeline.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
- TrialA Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialA Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
- AgentHRS-4357
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.